Could GLP-1 drugs become the first longevity medications? Scientists think it's possible

Could GLP-1 drugs become the first longevity medications? Scientists think it's possible

For years, billionaire biohackers and longevity entrepreneurs have promoted the idea that an “anti-aging drug” could slow — or even reverse — aging, often promising results well beyond what science supports.  But behind the hype, researchers in the burgeoning field of geroscience — which seeks to understand the biology of aging — have been investigating whether GLP-1 drugs like Ozempic and Zepbound do more than treat obesity and diabetes. Althou…

Dr Suruchi Vishwasrao, Sr Scientist, R&D, Merck Life Sciences

Speaker in this video: + Dr Suruchi Vishwasrao, Sr Scientist, R&D, Merck Life Sciences Topic: Peptide delivery, reimagined: Addressing hurdles and unlocking potential in oral administration Key Highlights: [1] Oral delivery is the next frontier for GLP-1 therapies. The industry is moving beyond injectables toward patient-friendly oral formulations. [2] Peptides face multiple barriers in the GI tract. Acidic pH, digestive enzymes, and poor intest…